In this week’s VJOncology podcast, we had the opportunity to attend the 2026 ESMO Gastrointestinal Cancers Congress in Munich, Germany, where we explored the latest advances across gastrointestinal malignancies. Join Teresa Macarulla, Vall d’Hebron University Hospital, Barcelona, Spain, Giulia Martini, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, Lorenza Rimassa, Hunimed University, Milan, Italy, Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan, and Silvio Ken Garattini, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, as they discuss emerging KRAS G12D-targeted therapies in pancreatic cancer, ctDNA-guided treatment strategies in metastatic colorectal cancer, novel targeted approaches for biliary tract cancer, HER2-directed therapies in gastroesophageal cancer, and evolving treatment paradigms in hepatocellular carcinoma and gastric cancer.

This week, VJOncology brings you lung cancer highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Join Alessandro di Federico from the Memorial Sloan Kettering Cancer Center, Erika Ruiz-Garcia of the Instituto Nacional de Cancerologia, Nandini Menon of the Tate Memorial Centre and Bjorn Henning Gronberg of the Norwegian University of Science and Technology as they discuss key trials and data in lung cancer from the meeting. They explore results from the LIBRETTO-432, TRITON and FLAME trials, as well as 7-year follow up data from the CROWN trial. In addition, they discuss two trials of KRAS G12C inhibitors, a study examining low-dose pembrolizumab and a trial of thoracic radiotherapy.

For this week’s VJOncology podcast, we bring you highlights in breast cancer

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL, where we explored the latest advances in gastrointestinal (GI) cancers. Join Ghassan Abou-Alfa and Yelena Janjigian of Memorial Sloan Kettering Cancer Center, Scott Kopetz of The University of Texas MD Anderson Cancer Center, and Choong-Kun Lee of Yonsei University as they discuss emerging treatment strategies in GI cancers, including findings from the EMERALD-3, RASolute 302, DESTINY-Gastric03, BREAKWATER, and HERBOT trials, alongside the growing role of targeted therapies, HER2-directed approaches, and biomarker testing in gastrointestinal oncology.

In this episode of VJOncology podcasts, we present highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Five leading experts share key data and insights spanning prostate cancer, sarcoma, lung cancer, colorectal cancer, and breast cancer. Dr Mary-Ellen Taplin from Dana-Farber Cancer Institute presents final analysis data from the PROTEUS trial, demonstrating that perioperative apalutamide plus androgen deprivation therapy (ADT) sets a new standard of care in high-risk localized prostate cancer. Dr Maggie Zhou from Stanford University highlights practice-changing findings in sarcoma, including the SARC041 trial of abemaciclib in dedifferentiated liposarcoma. Dr Abdul Rafeh Naqash from the University of Oklahoma Health Sciences Center reviews key lung cancer advances, including results from the DeLLphi-304, LIBRETTO-432, and ALCHEMIST trials. Dr Scott Kopetz from MD Anderson Cancer Center presents progression-free and overall survival data from BREAKWATER Cohort 3, supporting encorafenib plus cetuximab combined with FOLFIRI as a new standard of care in BRAF V600E-mutant metastatic colorectal cancer. Finally, Dr Kevin Kalinsky from Emory University discusses PFS2 data from ASCENT-04, reinforcing sacituzumab govitecan plus pembrolizumab as a standard of care in treatment-naive PD-L1-positive metastatic triple-negative breast cancer. This episode offers essential insights into practice-changing data across five major tumor types from one of the most important oncology meetings of the year.

In this roundtable discussion from iwCAR-T 2026, a panel of experts in cell therapy for solid tumours discuss the current state of CAR T-cell therapy beyond hematological malignancies. The panel explores key challenges including target selection, T-cell persistence, and the immunosuppressive tumour microenvironment, alongside emerging strategies such as armoured CARs, combination approaches with targeted therapies, and in vivo CAR T-cell generation. The discussion also addresses the importance of patient selection and earlier lines of therapy, and considers how academic–industry partnerships and evolving manufacturing technologies may shape the future of the field.

In this week’s VJOncology podcast, we mark Bladder Cancer Awareness Month by exploring recent advances in bladder cancer research and clinical care. Join Joaquim Bellmunt of Dana-Farber Cancer Institute, Boston, MA, Eva Compérat of Medical University of Vienna, Vienna, Austria, Roberto Contieri of Humanitas University, Milan, Italy, and Vadim Koshkin of University of California, San Francisco, CA, as they discuss circulating tumor DNA for MRD monitoring in muscle-invasive bladder cancer, advances in intravesical therapies and urinary tract diagnostics, de-escalated approaches for low-grade non-muscle-invasive disease, and the evolving molecular classification of bladder cancer into luminal and basal subtypes.

In this week’s VJOncology podcast, we bring you key updates from the 2026 AACR meeting across early-phase immuno-oncology and targeted therapy. Join leading experts Bruno Bockorny, Beth Israel Deaconess Medical Center, Boston, MA, Byoung Chul Cho, Yonsei University, Seoul, South Korea, Kristen Pauken, and Timothy Yap, MD Anderson Cancer Center, Houston, TX, as they discuss the clinical challenges of immune-related adverse events with checkpoint inhibitors, early signals from first-in-human studies of PLN-101095 in refractory solid tumors, emerging safety and activity data from a Phase I dose-escalation study of denikitug, and updated results of elisrasib monotherapy in previously treated KRAS G12C-mutant non-small cell lung cancer.

In this week's instalment of the VJOncology podcast, we examine the rapidly evolving treatment landscape of advanced non-small cell lung cancer, drawing on expert insights from ELCC 2026. This episode spans the breadth of precision oncology in NSCLC: from the clinical challenges of rare actionable alterations and emerging targeted agents, to the growing complexity of first-line treatment sequencing, and the arrival of a promising new immunotherapy class in thoracic oncology. Leading clinicians and researchers from the Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, and Lausanne University Hospital discuss BRAF non-V600E mutations, KRAS G12C, HER2-mutant disease, EGFR exon 20 insertions, amivantamab-based combinations, and the evolving role of bispecific T-cell engagers in NSCLC and mesothelioma. This episode provides actionable insight for clinicians navigating an increasingly crowded and competitive treatment landscape in advanced NSCLC.

In this week’s VJOncology podcast, we mark Head and Neck Cancer Awareness Month by exploring recent advances in head and neck cancer. Join Kevin Harrington, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, Takeshi Kodaira, Aichi Cancer Center, Nagoya, Japan, Andreas Dietz, University Hospital of Leipzig, Leipzig, Germany, and Nabil Saba, Emory University, Atlanta, GA, as they discuss key clinical trial updates, including OrigAMI-4, ASPEN-04, CompARE, and JCOG1912, alongside evolving strategies optimizing radiation dosing, reducing late toxicities, and improving management of recurrent respiratory papillomatosis.